New Prostate Cancer Test Shows Superior Accuracy Over PSA Screening

A revolutionary prostate cancer test developed in Sweden shows promising results, potentially transforming early detection and treatment strategies

The landscape of prostate cancer detection may be on the brink of a significant transformation, thanks to a groundbreaking test developed in Sweden. Known as Stockholm3 this innovative tool has demonstrated superior accuracy in identifying clinically significant prostate cancers compared to the traditional PSA test.

Prostate cancer remains the most prevalent form of cancer among men in the UK with approximately one in eight men affected. Each year, around 63,000 new cases are diagnosed, and 12,000 deaths are attributed to this disease. The current standard for assessing prostate cancer risk is the PSA test which measures levels of a protein produced by the prostate gland.

However, this test has faced criticism for its tendency to produce false-positive results and miss aggressive tumors.

Stockholm3: A More Accurate Approach

The Stockholm3 test developed by researchers at the Karoline Institute in Stockholm, combines multiple factors to generate a comprehensive risk score.

This score estimates a man’s likelihood of having clinically significant prostate cancer, defined as anything above grade two of the disease. The test integrates PSA measurements with genetic markers, relevant proteins in the blood, and personal factors such as age, family history, and previous biopsy results.

A study involving 12,670 men aged between 50 and 74, with an average age of 62, compared the effectiveness of the Stockholm3 test with the standard PSA test. Among those screened, 443 were diagnosed with clinically significant prostate cancer. The results were compelling: Stockholm3 identified 90% of these cancers, compared to 74% detected by the PSA test. Over a two-year follow-up period, the new test missed just 10% of clinically significant cancers, whereas the PSA test missed 26%. The rate of false positives was similar for both tests.

Addressing the Limitations of PSA Testing

One of the primary criticisms of the PSA test is its lack of specificity. Levels of PSA can rise due to various factors other than prostate cancer, such as infections and advancing age. This can lead to unnecessary scans and biopsies, causing anxiety and potential complications for patients. The Stockholm3 test aims to address these limitations by providing a more nuanced and accurate assessment of prostate cancer risk.

The researchers acknowledged some limitations in their study, including the fact that only around a quarter of the men invited to participate chose to take part. However, they believe their findings warrant further investigation. They emphasized the need for longer-term follow-up to evaluate the long-term effects and cost-effectiveness of this screening approach. If confirmed, integrating Stockholm3 into screening pathways could significantly improve the efficiency and clinical utility of prostate cancer screening programs.

Alternative Approaches and Future Directions

Just weeks after the Stockholm3 study, another research suggested that using MRI scans as an alternative approach to testing for prostate cancer could be more effective than current screening methods used by the NHS. Under this proposed approach, men would be offered an MRI after receiving a positive PSA test, before any biopsy is considered. This step would allow doctors to act on lower PSA levels and detect cancers earlier.

The panel recommended a more personalized approach to screening, based on individual risk factors. Men at low risk of the disease would be offered an MRI every four to five years, while those at higher risk, such as black men and those with a genetic predisposition, should be screened more frequently. Biopsies, which can be painful and lead to sexual problems, should only be carried out if MRI scans flag clearly suspicious results. This stricter, more personalized approach could slash biopsies in half while detecting roughly the same amount of cancers.

Earlier this month, government advisors rejected calls for a nationwide prostate cancer screening program. However, it was announced that all black men in the UK would be invited to join a prostate cancer screening trial. Health secretary James Murray accepted a recommendation to restrict access to a new national screening program to as few as 1,500 people but committed to expanding an ongoing trial into diagnostic tests and scans. This trial would include all black men aged 45 to 74 who have not had a PSA test or MRI prostate scan in the past five years.

The Daily Mail is among those campaigning to end needless prostate cancer deaths and for a national screening program, initially targeted at high-risk men. Jeremy Clarkson recently revealed he had been diagnosed with the disease but confirmed he is now in remission. These developments highlight the ongoing efforts to improve prostate cancer detection and treatment strategies, offering hope for better outcomes in the future.